Astria Therapeutics, Inc. has announced that it will present new clinical data at the 2025 US Hereditary Angioedema Association National Summit. The company is set to present four posters, showcasing various aspects of its ongoing research. Timothy Craig, D.O., will provide an encore presentation on the global Phase 3 trial of navenibart in hereditary angioedema patients. Michael E. Manning, M.D., will present initial safety and efficacy data from the Phase 1b/2 and long-term open-label trials. Mindy DeMarco, RN, will address recruitment challenges in rare disease trials, while H. Henry Li, M.D., will discuss interim results on attack severity reduction from the ALPHA-STAR trial. The results will be presented during the summit, taking place from July 10-13, 2025, in Baltimore, Maryland.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.